Clinical Scorecard: Case Study: Recurrence of Felty Syndrome Triggered by Immunotherapy in a Metastatic Melanoma Patient

At a Glance

Key Highlights

• Immune checkpoint inhibitors can exacerbate pre-existing autoimmune conditions.
• Felty syndrome is characterized by neutropenia and splenomegaly.
• Rapid neutrophil recovery can be achieved with immunosuppressive therapy.
• Close monitoring is essential for patients with a history of autoimmune diseases undergoing immunotherapy.
• Differential diagnosis of neutropenia should include immunotherapy-related causes.

Guideline-Based Recommendations

Diagnosis

• Consider immunotherapy-induced Felty syndrome in patients with neutropenia and a history of rheumatoid arthritis.

Management

• Initiate moderate immunosuppression promptly in cases of Felty syndrome recurrence.

Monitoring & Follow-up

• Regular blood monitoring for absolute neutrophil count in patients receiving immune checkpoint inhibitors.

Risks

• Increased risk of severe neutropenia and infections in patients with pre-existing autoimmune conditions.

Patient & Prescribing Data

71-year-old male with metastatic melanoma and a history of seropositive rheumatoid arthritis.

Combination therapy with nivolumab and relatlimab led to neutropenia; management included G-CSF and corticosteroids.

Clinical Best Practices

• Collaborative care between oncology and rheumatology teams is crucial.
• Early identification of immune-related adverse events can prevent complications.
• Use of granulocyte colony-stimulating factor (G-CSF) for neutropenia management.

References

• Immune Checkpoint Inhibitors and Autoimmunity
• Felty Syndrome Overview
• Management of Neutropenia in Cancer Patients